edrecolomab + fluorouracil + folinic acid

This is a combination therapy consisting of edrecolomab, fluorouracil, and folinic acid. Edrecolomab is a murine monoclonal antibody targeting the cell-surface glycoprotein EpCAM (also known as 17-1A), which is expressed on epithelial tissues and various carcinomas. Fluorouracil (5FU) is a pyrimidine analog that acts as an antimetabolite chemotherapeutic agent by inhibiting thymidylate synthase, thereby disrupting DNA synthesis in rapidly dividing cells. Folinic acid (leucovorin) enhances the cytotoxic effects of fluorouracil by stabilizing the binding of its active metabolite to thymidylate synthase. This combination was investigated for adjuvant treatment in patients with resected stage III colon cancer but did not demonstrate improved overall or disease-free survival compared to standard chemotherapy with fluorouracil and folinic acid alone[1][3][5]. The regimen was generally well tolerated; however, hypersensitivity reactions were more common with edrecolomab.